Modern targeted drug plus old malaria pill serve a one-two punch in advanced cancer patients

Researchers may have found a way to turn an adaptive cellular response into a liability for cancer cells, by treating a group of patients with several different types of advanced cancers with temsirolimus, a molecularly targeted cancer drug that blocks nutrient uptake, plus hydroxychloroquine, an anti-malarial drug that inhibits autophagy. This regimen halted tumor growth in two-thirds of the patients.

Read the whole article on Science Daily

More from Science Daily